The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are: * Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori? * What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori. Participants will: * Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy * Visit the clinic once every 1 week for checkup and questionnaire filling * Check for H pylori eradication after treatment
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
70
The drug will be supplied randomly to the group I
Will be supplied randomly to Group II
Kafrelsheikh University
Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt
Eradication rate
How much the H pylori eradication rate following the treatment
Time frame: 2 weeks of continuous treatment, followed by 2 weeks of treatment and then testing again for presence\absence of the infection
Safety profile
The side effects related to the used medications (triple therapy and lignin)
Time frame: up to 4 weeks (2 weeks active treatment and 2 weeks after treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.